Streetbeat News

Revenues

ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years with an average annual return of 14.17%. A $100 investment in ALNY 15 years ago would be worth $744.03 today. The company currently has a market capitalization of $20.11 billion.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 4:01 pm

HBAN

Analysts' ratings for Huntington Bancshares (NASDAQ:HBAN) over the last quarter show a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $15.71. Despite some positive ratings, the company faces challenges with declining revenue, low net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 4:00 pm

ALB

Over the past three months, 11 analysts have evaluated Albemarle (NYSE:ALB), with a range of opinions from bullish to bearish. The average 12-month price target is $144.27, with a high of $160.00 and a low of $124.00. Recent analyst actions include both raises and lowers in ratings and price targets, reflecting mixed sentiments. Albemarle, a major lithium producer, faces challenges with revenue growth and return metrics but maintains a strong net margin and conservative debt management.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 4:00 pm

TGT

Target Corp (NYSE:TGT) has successfully addressed a significant inventory challenge during the COVID-19 pandemic under the leadership of Chief Supply-Chain and Logistics Officer Gretchen McCarthy. By transforming retail spaces into distribution hubs and integrating advanced inventory management technologies, Target reduced its inventory by nearly $2 billion over two years. Despite reporting a lower-than-expected adjusted EPS in the recent first-quarter FY24 earnings, Target's inventory management strategy has positioned the company to better cater to both in-store and online shopping demands.

Portfolio Pulse from Shivani Kumaresan

June 13, 2024 | 3:59 pm

AAPL

AMZN

AVGO

GLD

GOOG

META

MSFT

NVDA

QQQ

SLV

SPY

TSLA

USO

The article discusses the impact of lower Producer Price Index (PPI) and higher jobless claims on the stock market, highlighting extremely positive sentiment driven by various factors including Elon Musk's pay package approval and Broadcom's stock split. It also mentions the early trade money flows in major tech stocks and ETFs, and provides insights on gold, oil, and Bitcoin trading activities.

Portfolio Pulse from The Arora Report

June 13, 2024 | 3:31 pm

WRB

WR Berkley (NYSE:WRB) has significantly outperformed the market over the past 15 years, delivering an average annual return of 14.82%. A $1000 investment in WRB 15 years ago would be worth $7,847.64 today. The company's current market capitalization is $19.91 billion.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 3:30 pm

MUSA

Murphy USA (NYSE:MUSA) has significantly outperformed the market over the past 5 years, delivering an average annual return of 41.09%. A $1000 investment in MUSA 5 years ago would be worth $5,651.50 today. The company's current market capitalization is $9.82 billion.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 3:30 pm

MULN

Mullen Automotive Inc (NASDAQ:MULN) shares are volatile after its Bollinger Motors division secured an order for 80 all-electric Class 4 commercial trucks worth $13.2 million. The trucks will be delivered to Momentum Groups, a fleet management and EV charging solutions provider, in the second half of the year. Bollinger Motors also qualified for federal clean vehicle purchasing incentives under the Inflation Reduction Act.

Portfolio Pulse from Adam Eckert

June 13, 2024 | 3:23 pm

ETHUSD

Ethereum's recent weak performance has dampened trader enthusiasm, but better price action is forecasted in the upcoming months. Prominent traders and analysts discuss market manipulation, whale activity, and key support levels. Significant net outflows from Coinbase and increased whale purchases are noted.

Portfolio Pulse from Khyathi Dalal

June 13, 2024 | 3:18 pm

STSS

Sharps Technology Inc. (NASDAQ:STSS) shares surged after the company signed a $30 million purchase order with Nephron Pharmaceuticals. This order is part of a larger five-year, $200 million syringe sales agreement. The deal is expected to close by the end of July.

Portfolio Pulse from Erica Kollmann

June 13, 2024 | 3:14 pm